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Introduction: The efficacy of epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors in EGFR mutation-positive non–small-cell 
lung cancer (NSCLC) patients necessitates accurate, timely testing. 
Although EGFR mutation testing has been adopted by many laboratories 
in Asia, data are lacking on the proportion of NSCLC patients tested in 
each country, and the most commonly used testing methods.
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Methods: A retrospective survey of records from NSCLC patients 
tested for EGFR mutations during 2011 was conducted in 11 Asian 
Pacific countries at 40 sites that routinely performed EGFR mutation 
testing during that period. Patient records were used to complete an 
online questionnaire at each site.
Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% 
confidence interval: 31.2%–32.5%) were tested for EGFR mutations. 
The rate of EGFR mutation positivity was 39.6% among the 10,687 
cases tested. The majority of samples were biopsy and/or cytology sam-
ples (71.4%). DNA sequencing was the most commonly used testing 
method accounting for 40% and 32.5% of tissue and cytology samples, 
respectively. A pathology report was available only to 60.0% of the 
sites, and 47.5% were not members of a Quality Assurance Scheme.
Conclusions: In 2011, EGFR mutation testing practices varied 
widely across Asia. These data provide a reference platform from 
which to improve the molecular diagnosis of NSCLC, and EGFR 
mutation testing in particular, in Asia.
Key Words: EGFR mutation, Non–small-cell lung cancer, Testing, 
Survey, Multicenter.
(J Thorac Oncol. 2015;10: 438–445)
Non–small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers,1 with an estimated 
1.8 million new lung cancer cases worldwide in 2012, includ-
ing 1 million cases in the Southeast Asian and Western Pacific 
regions combined.2
Recent advances in lung cancer research have resulted 
in the identification of several mutations that contribute to car-
cinogenesis of NSCLC.1,3 The epidermal growth factor recep-
tor (EGFR) is encoded by one of the most commonly mutated 
genes in NSCLC, with activating mutations detected in up to 
15% of adenocarcinoma (ADC) and less than 5% of squamous 
cell carcinomas (SCC) within the Caucasian patient popula-
tion.1,4 Mutation rates are higher in Asian populations, with 
EGFR mutations reported in up to 59% of ADC and 5.4% of 
SCC cases.5 Mutations are also more common in never-smok-
ers and women patients.6 The landmark Iressa Pan-Asia Study 
was the first Phase III study to demonstrate improved progres-
sion-free survival, response rate, symptom control, and qual-
ity of life in EGFR mutation-positive patients treated with an 
EGFR-tyrosine kinase inhibitor compared with doublet che-
motherapy.5 Subsequent Phase III trials confirmed this find-
ing.5,7–11 EGFR mutations are now well recognized as the most 
potent predictive biomarkers of treatment outcome to first-
line EGFR-tyrosine kinase inhibitors, confirming the need for 
accurate, timely EGFR mutation testing worldwide.5,12,13
Although EGFR mutation testing has been adopted by 
many laboratories in Asia, accurate data are lacking on the 
proportion of NSCLC patients tested in each country, and the 
most commonly used testing methods. For example, a previ-
ous study showed that in 2010, the EGFR mutation testing rate 
was less than 10% in China because of the limited prevalence 
of testing technology.14 To increase the understanding of real-
world testing practices in this region, a formal internet-based 
survey of EGFR mutation testing practices was conducted in 
centers throughout Asia Pacific. The aim of the survey was 
to gather information about the NSCLC population in Asia 
Pacific that is tested for EGFR mutations, along with the pro-
portion tested, the outcomes of EGFR mutation testing, and 
the most commonly used testing methods and sample types.
MATERIALS AND METHODS
Participating Sites and Study Design
A retrospective database survey of records from NSCLC 
patients tested for EGFR mutations from January 1, 2011 to 
January 1, 2012 was conducted at participating sites in 11 
countries across the Asia Pacific region. Site eligibility was 
assessed using feedback obtained by Astra Zeneca affiliate 
offices in each country. Of 71 sites initially shortlisted, 40 sites 
were selected as being both eligible and willing to participate. 
Eligible sites had to perform EGFR mutation testing for clini-
cal purposes, and should have tested at least 100 samples from 
NSCLC cases during this period. If, in a given country, no site 
could meet these criteria, the site that performed the highest 
number of EGFR mutation tests during this period was sur-
veyed. On-site training was given to ensure that the survey 
was completed according to the study protocol.
The survey took the form of an online questionnaire using 
SurveyMonkey Inc. (Palo Alto, CA) that was available in English 
(Supplementary data, Supplementary Digital Content 1, http://
links.lww.com/JTO/A741), Japanese, and Chinese. The survey 
was completed between April 1 and November 1, 2013 by a qual-
ified individual at each site (pathologist, oncologist, or labora-
tory head) who had access to data sources containing information 
about the tested NSCLC population, i.e., patient and laboratory 
records. Survey response data were stored in a central database 
that was not accessible to the investigators until the survey clos-
ing date, and the survey was programmed so that responders were 
only able to complete the questionnaire once.
On the survey closing date, the final dataset was down-
loaded from the central online database into a Microsoft Excel 
spreadsheet. Data quality was assured via an independent 
check of the data. Any data discrepancies were queried with 
the respective sites, and the data were corrected if appropriate. 
Where discrepancies could not be resolved or explained, the 
data were treated as missing and only the validated, cleaned 
data were used in the analyses.
This noninterventional retrospective study was per-
formed in accordance with ethical principles that are consis-
tent with the Declaration of Helsinki, International Conference 
on Harmonisation Good Clinical Practice guidelines, and the 
applicable legislation on Non-Interventional Studies. Patient-
level data were not reported, hence patient consent was not 
required. The protocol was approved by the Institutional 
Review Board for each site.
Study Objectives
The primary objective of the study was to determine the 
number of NSCLC patients who were tested for EGFR muta-
tions at the surveyed sites, to estimate the rate of EGFR muta-
tion positivity in the tested samples: overall, and by NSCLC 
histological subtype, sex, and smoking status.
Secondary objectives were: (1) to estimate the propor-
tion of NSCLC patients who were tested in the participating 
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countries: overall, and by NSCLC histological subtype, sex 
and smoking status (this was calculated based on responses 
regarding all NSCLC patients who were newly diagnosed at 
the hospitals from which participating sites received samples 
from January to December 2011); (2) to determine which 
EGFR mutation testing methods are most commonly used in 
the participating countries and the characteristics of samples 
tested; and (3) to evaluate the source of the captured data and 
utilize this information to interpret the outcomes. To this end, 
questions were included in the survey to determine the type 
of laboratories (commercial or hospital, and whether they test 
samples from only their own or from several hospitals); QA 
scheme participation; accreditation by a local or international 
accrediting body; and the turnaround time for testing, defined 
as the period from which the sample is received by the labora-
tory to when the report is sent out. The survey also included 
questions about the nature of the source records (paper or 
electronic). Respondents were asked whether the source 
records were centrally located, contained data from all avail-
able patients, were stored consecutively so that no patients 
could have been missed, and whether or not there was a pos-
sibility of duplicate records among the source records.
Statistical Methods
Where provided, the number of NSCLC patients who 
were tested for EGFR mutations during 2011 was reported. 
The proportions of EGFR mutation-positive patients were cal-
culated along with the 95% confidence interval based on the 
Wilson score method in the overall study population, as well 
as for subgroups based on histological subtypes and demo-
graphic factors. Other variables were summarized descrip-
tively. If the answer to a question about the number of cases in 
a subgroup was “Not known”, then the data from that site were 
not used to calculate the proportions stated above.
Role of Funding
This investigator-initiated study was funded by 
AstraZeneca. Employees of the sponsor (AstraZeneca) played 
a role in the study design, data analysis, data interpretation, 
and writing the report. The corresponding author had full 
access to all data and was responsible for the decision to sub-
mit for publication.
RESULTS
Assurance of the Data Reliability
Asked about the type of data source records the partici-
pating sites consulted to provide answers to the survey ques-
tions, 67.5% used hospital electronic records, 55.0% used 
laboratory electronic records, 35.0% used laboratory paper-
based records, and 15.0% used hospital paper-based records, 
with several sites using multiple data sources. In the subset 
of sites that used paper-based records, 15 sites responded 
that they were stored in a single central location, and one 
site responded that each laboratory staff member stored their 
own records. At 95.0% of sites, the records used contained 
all available patient data and at 82.5% of sites, records were 
confirmed as being collected consecutively. Data were not 
collected consecutively at 17.5% sites, meaning that some 
patients could have been missed; three sites (7.5%) indicated 
a possibility of duplicates among the source records.
Proportion, Demographics and Histology of 
NSCLC Patients Tested for EGFR Mutation
Respondents from 40 sites in 11 Asian Pacific countries 
successfully completed the survey: China (nine sites); Hong 
Kong (two sites); Indonesia (one site); Japan (eight sites); 
Korea (eight sites); Malaysia (one site); Philippines (one 
site); Singapore (one site); Taiwan (six sites); Thailand (two 
sites); and Vietnam (one site). Of the 22,193 patients who 
were reported as diagnosed with NSCLC at hospitals that sent 
samples to the participating sites during 2011, 31.8% over-
all were tested for EGFR mutations (Table 1, Supplementary 
Table S1.1, Supplementary Digital Content 2, http://links.lww.
com/JTO/A742). The highest EGFR mutation testing rate was 
observed in Japan (64.8%), and the lowest in China (18.3%). 
Data on total NSCLC cases diagnosed were not provided by 
the participating sites in Indonesia, Malaysia, Singapore, the 
Philippines or Vietnam, so the EGFR mutation testing rate 
could not be calculated for those countries. Not all sites in 
China, Thailand and Korea were able to provide these data; 
hence, the testing rates for those countries were based only on 
data from the sites that provided it.
In all countries, a larger proportion of women than 
men patients with NSCLC were tested for EGFR mutations 
(Table 1, Supplementary Table S1.1, S1.2, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A742). Smoking 
status amongst tested patients varied widely between coun-
tries; proportions with a history of smoking who were tested 
ranged from 27.1% in Korea to 68.8% in Japan.
In the survey, histological groupings were defined as 
ADC or “other morphological subtypes,” with SCC cases 
included as a subset of “other.” Overall, 50.4% of patients 
with ADC-subtype NSCLC were tested for EGFR mutations, 
compared with 12.5% of those with other morphology and 
12.5% of those with SCC (Table 1, Supplementary Table S1.3, 
Supplementary Digital Content 2, http://links.lww.com/JTO/
A742). The proportion of histology subtypes tested was gen-
erally similar in all countries except for Japan, where 55% of 
non-ADC morphology and 50.3% of SCC cases were tested.
EGFR Mutation Positivity in Relation 
to Demography and Histology 
at Participating Sites
Data on EGFR mutation positivity rates were avail-
able from all sites included in the analysis. Of the 10,687 
cases tested for EGFR mutation that were surveyed (Table 2, 
Supplementary Table S2.1, Supplementary Digital Content 
2, http://links.lww.com/JTO/A742), 39.6% (95% confidence 
interval [CI]: 38.7%–40.5%) were EGFR mutation-positive, 
with mutation positivity rates varying between countries. 
EGFR mutation frequency was higher in samples from woman 
(56.5% overall, 95% CI: 55.0%–58%) than from men (27.8%, 
95% CI: 26.6%–29.0%) in all countries except Indonesia, and 
from never-smokers (60.8%, 95% CI: 58.6%–63.0%) than 
from current or ex-smokers (27.4%, 95% CI: 25.6%–29.4%; 
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Table 2, Supplementary Table S2.1, S2.2, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A742).
The frequency of EGFR mutation positivity among the 
different histological subgroups was 46.5% (95% CI: 45.4%–
47.6%) overall in ADC samples, 13.3% (95% CI: 11.7%–
15.0%) in tumor samples with other morphologies, and 7.6% 
(95% CI: 6.1%–9.6%) in SCC samples (Table 2, Supplementary 
Table S2.3, Supplementary Digital Content 2, http://links.lww.
com/JTO/A742). The proportion of samples where the EGFR 
mutation test did not yield a result was low—1.1% overall.
Sample Types, EGFR Mutation Testing 
Methods and Pathology Support
The majority of samples tested for EGFR mutations 
were biopsy and/or cytology samples (71.4% overall; Fig. 1). 
High proportions of EGFR mutation tests on cytology sam-
ples were carried out in Indonesia (98.0%), the Philippines 
(73.3%), and Vietnam (66.7%). Overall, 75.6% of the tested 
samples came from the primary tumor, 21.1% were from a 
metastatic site (including pleural effusion), and 3.3% came 
from an unknown site.
TABLE 1.  Proportion of NSCLC Patients who were Tested for EGFR mutations during 2011
Country (n Cases Diagnosed 
with NSCLCa)
Proportion Tested for EGFR 
Mutations % (95% CIc)
Proportion of Men/Woman, Smokers and Nonsmokers, and Histological Subtypes 
that were Tested for EGFR Mutationsd
Sex Smoking Status Histology
Men/Woman (%)
Current + Ex-Smoker/Never 
Smoker (%)
ADC/Other Morphological 
Subtypes/Only SCC (%)
Total (22,193) 31.8 (31.2–32.5) 26.9/40.2 47.0/57.4 50.4/12.5/12.5
China (12,086b) 18.3 (17.6–19.0) 15.2/25.3 N.D. 30.3/8.0/9.4
Hong Kong (795) 42.0 (38.6–45.5) 36.2/52.3 34.1/52.1 55.4/9.0/6.4
Japan (2379) 64.8 (62.9–66.7) 63.6/67.0 68.8/68.3 69.2/55.0/50.3
Korea (3794) 33.5 (32.0–35.0) 26.1/38.1 27.1/42.9 62.7/9.8/8.3
Taiwan (2890) 54.3 (52.5–56.1) 47.1/64.3 37.0/56.8 69.3/15.5/8.5
Thailand (249b) 57.8 (51.6–63.8) 51.6/69.3 49.5/84.7 83.6/7.1/6.9
Numbers of patients tested and denominators for each subgroup are shown in Supplementary Table S1.1, S1.2, and S1.3. Data on total NSCLC patients diagnosed were not 
available from Indonesia, Malaysia, the Philippines, Singapore, or Vietnam. “ADC” includes ADC and other characteristics in ADC category. “Other morphological subtypes” includes 
adenosquamous and histologies with other non-ADC characteristics. “SCC” is a subset of “other morphological subtypes.”
aTotal NSCLC patients diagnosed at participating sites during 2011.
bNot all sites provided data on number of NSCLC cases diagnosed.
cWilson score confidence interval.
dNot all sites provided data for sex, smoking status, and histology.
NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma; N.D., no data.
TABLE 2. EGFR Mutation Positivity at Participating Sites, Overall and by Demography and Histology
Country (n Cases Tested for 
EGFR Mutations)
EGFR Mutation-Positive 
Cases % (95% CIa)
Frequency of EGFR mutation positivity inb:
Men/Woman (%)
Current + Ex-Smoker/Never 
Smoker (%)
ADC/Other Morphological 
Subtypes/Only SCC (%)
Total (10,687) 39.6 (38.7–40.5) 27.8/56.5 27.4/60.8 46.5/13.3/7.6
China (2694) 38.1 (36.3–39.9) 26.5/53.9 40.0/57.6 47.5/14.9/10.1
Hong Kong (334) 48.2 (42.9–53.6) 34.2/65.3 28.9/64.3 50.7/58.3/14.3
Indonesia (101) 28.7 (20.8–38.2) 28.8/28.6 N.D. 27.6/32.0/25.0
Japan (1542) 30.2 (28.0–32.6) 18.1/52.9 19.5/56.5 39.3/5.6/3.0
Korea (2950) 35.8 (34.1–37.6) 24.0/53.3 25.6/50.6 43.0/11.1/5.7
Malaysia (352) 45.7 (40.6–51.0) 35.3/57.6 N.D. 45.7/N.S
Philippines (90) 38.9 (29.5–49.2) 25.0/57.9 16.0/66.7 41.5/0/0
Singapore (562) 42.9 (38.9–47.0) 27.7/63.3 N.D. 45.5/100.0c/100.0c
Taiwan (1569) 53.3 (50.8–55.7) 42.9/63.9 43.3/66.0 55.6/26.4/22.6
Thailand (443) 45.1 (40.6–49.8) 31.8/56.8 45.7/66.0 45.8/18.2/20.0
Vietnam (50) 36.0 (24.1–49.9) 27.6/47.6 18.2/66.7 36.0/N.S.
Numbers of EGFR mutation-positive samples and denominators for each subgroup are shown in Supplementary Table S2.1, S2.2 and S2.3. Mutation frequency is based on 
the number of samples, and may include multiple samples per patient. “ADC” includes ADC and other characteristics in ADC category. “Other morphological subtypes” includes 
adenosquamous and histologies with other non-ADC characteristics. “SCC” is a subset of “other morphological subtypes.”
aWilson score confidence interval.
bNot all sites provided data for sex, smoking status, and histology.
cOnly one sample was tested.
EGFR, epidermal growth factor receptor; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma; N.D., no data; N.S. no samples tested.
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Seventy-five per cent of sites reported routine use of 
immunohistochemistry (IHC) to predict the subtypes of sam-
ples that had poorly differentiated morphology. A pathology 
report was available to 60.0% of the participating testing sites, 
with a further 17.5% of sites indicating that a pathology report 
was sometimes available.
DNA sequencing was cited as the most commonly used 
EGFR mutation testing method for both tissue and cytology 
samples by the largest proportion of participating sites overall 
(Fig. 2), but the most commonly used methods varied among 
countries. PCR-INVADER was the most commonly used 
test in 50.0% of Japanese sites for both tissue and cytology 
samples, followed by PNA-LNA PCR clamp (37.5% of sites). 
PNAClamp Mutation Detection was the most commonly used 
method for testing cytology samples at 50% of Korean sites 
and 33.3% of sites in China selected “other commercial in 
vitro diagnostic kit” as their most common testing method for 
tissue samples. Most laboratories (70.0%) had a turnaround 
time of 5–10 days, and 20.0% had a turnaround time of less 
than 5 days.
Mutation Testing Laboratories
Participating sites included commercial and hospital 
laboratories; the largest proportion (57.5%) comprised hospi-
tal laboratories that tested samples from their own and other 
hospitals (Fig. 3A). Local accreditation was more common 
than accreditation by international accrediting bodies (Fig. 
3B), with 20.0% of participating sites (all in Japan) being 
neither accredited nor participating in a Quality Assurance 
scheme. Only 52.5% of the surveyed sites were members of a 
Quality Assurance scheme (Fig. 3C).
DISCUSSION
This large retrospective database study of more than 
22,000 newly diagnosed NSCLC patients from 40 sites pro-
vides insight into the “real-world” EGFR mutation testing 
practices in Asia in 2011. The frequency of EGFR mutation 
positivity in the EGFR mutation-tested NSCLC population 
was 39.6% overall, in line with the EGFR mutation frequency 
reported in Asia.15,16 The variations in EGFR mutation posi-
tivity between countries are likely the result of differences in 
clinical/case selection of the tested populations (e.g., the pres-
ence or absence of reimbursement for testing within healthcare 
systems, proportion of smokers, or larger or smaller propor-
tions of ADC samples being tested [Supplementary Figure, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A743]), and also possibly due to differences in EGFR muta-
tion testing methods.17 For example, Japan had the lowest rate 
of EGFR mutation positivity of all countries surveyed, but 
tested a wider spectrum of patients, including 63.6% of men 
and 68.8% of smokers, which was substantially higher than 
the average testing rates in these patient groups elsewhere in 
the region (Supplementary Figure, Supplementary Digital 
Content 3, http://links.lww.com/JTO/A743). In addition, 
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FIGURE 1.  Nature of samples tested for EGFR mutations at participating sites. No data were available for Malaysia. †Data from 
responses to question: “(Amongst NSCLC cases tested for EGFR mutations in your laboratory, what is the) number of surgical 
specimen samples tested?” ‡Data from responses to question: “(Amongst NSCLC cases tested for EGFR mutations in your laboratory, 
what is the) number of biopsy and/or cytology samples tested?” §Data from responses to question: “How many samples tested 
for EGFR mutation during 2011 were cytology samples?” Proportions of biopsy and/or cytology samples and of surgical specimens 
were calculated using data from only those sites that provided answers to both questions on “NSCLC samples that were biopsy 
and/or cytology samples” and “NSCLC samples that were surgical specimens.” The proportions of cytology samples were 
calculated using data from the sites that provided answers to all three questions, i.e., on “NSCLC samples that were biopsy and/
or cytology samples,” “NSCLC samples that were surgical specimens” and “NSCLC samples that were cytology samples.” EGFR, 
epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.
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Japan reported higher testing rates in non-ADC NSCLC 
samples (55.0%) than any other country, most likely because 
EGFR mutation testing is reimbursed for all patients with lung 
cancer in this country.
The EGFR mutation frequency observed in the differ-
ent histological subtypes was also generally in line with pub-
lished reports.15,16 However, EGFR mutation in SCC samples 
appeared to be higher than expected in some countries. This 
finding might be associated with poor cooperation between 
pathology and molecular testing laboratories: 40% of the 
laboratories did not always refer to the pathology report and 
25% did not use IHC to subtype poorly differentiated tumors. 
Therefore, EGFR testing can be considered even in patients 
with SCC if the clinicopathological features suggest the pos-
sibility of EGFR mutations. This is in agreement with molec-
ular testing guidelines published by experts representing the 
College of American Pathologists, International Association 
for the Study of Lung Cancer, and Association for Molecular 
Pathology (CAP/IASLC/AMP).18
Data on total NSCLC cases diagnosed were not avail-
able in Indonesia, Malaysia, the Philippines, Singapore, or 
Vietnam; hence, the proportion of cases tested for EGFR muta-
tions could not be estimated for those countries. Japan, where 
mutation testing for cancer is well established, had a relatively 
high EGFR mutation testing rate (64.8%), mainly because (1) 
sample logistics and testing are well established and are largely 
carried out in a centralized manner at three major commer-
cial laboratories, and (2) cytology samples are routinely tested 
due to the practice of using methods optimal for these sam-
ples (i.e., sensitive allele-specific PCR-based methods in all 
sites),19 which increases the ability to test for EGFR mutations 
in patients from whom tumor tissue samples are not available.
In all countries, the majority of samples tested for EGFR 
mutations were biopsy or cytology samples. The use of tissue 
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resections or biopsies is generally preferable for EGFR muta-
tion testing because of the greater amount of sample that is 
available. However, in many countries, cytology samples are 
commonly used for EGFR testing despite the common use of 
direct sequencing. As recommended in the CAP/IASLC/AMP 
molecular testing guidelines,18 more sensitive assays should 
be applied for patients in whom only cytology samples are 
available. Increasingly, cytology cell blocks are being used 
to provide adequate material for additional molecular tests, 
including anaplastic lymphoma kinase IHC and fluorescence 
in situ hybridization (FISH). Cell block preparation of cytol-
ogy specimens is recommended in recently published molec-
ular testing guidelines for treatment selection among lung 
cancer patients.18 It will be interesting to see how the uptake of 
new methodologies, such as next-generation sequencing and 
multiplex panels, impacts testing in the future.
Only 60% of the survey’s participating sites routinely 
received pathology information such as percentage tumor 
content along with the samples they tested, and this is an area 
that could be targeted for improvement. Particularly, EGFR 
testing is conducted frequently with small biopsy/cytology 
samples, in which false negative results can occur more fre-
quently due to insufficient cancer cell contents and poor DNA 
quantity. Therefore, the CAP/IASLC/AMP guideline recom-
mends active engagement of pathologists to molecular testing, 
i.e., checking the adequacy of specimens.18 The turnaround 
time was generally acceptable, with all sites generating EGFR 
mutation test results within 15 days (and 20% within 5 days). 
Further improvements may help ensure that patients receive 
results in a more timely manner to facilitate appropriate first-
line treatment decisions, particularly for urgent cases.
As a retrospective database survey, this study had limi-
tations. Not all the testing sites had access to data on num-
bers of patients diagnosed with NSCLC at the hospitals from 
which they received samples; hence, proportions of NSCLC 
patients tested could not be calculated for some countries. Not 
all sites were able to provide answers to all the questions, and 
thus some calculations, for example the proportion of EGFR 
mutation positivity in men versus woman, and in smokers ver-
sus nonsmokers, were performed on the subset of data gener-
ated from responses that were received. At a minority of sites 
(4 of 40), the number of samples used in diagnosis or tested 
for EGFR mutations exceeded the number of patients tested. 
This was explained, in most cases, by the testing of more than 
one sample from a single patient, for example following dis-
ease progression or via a secondary biopsy. EGFR mutation 
status in Table 2 was reported on a per-patient basis, and so 
was not impacted by the issue of multiple samples. The lack 
of exact matching of samples to patients meant that sample 
data (Fig. 1) could not be directly linked back to patients in 
all cases, although it should be noted that the discrepancy 
between the number of samples diagnosed and number of 
patients was less than 0.5%. Another potential source of con-
cern was the nature and quality of the data. However, given 
that 38 of 40 (95.0%) sites used source records containing all 
available patient data; at 33 of 40 (82.5%) sites, records were 
collected consecutively; and only three sites (7.5%) noted a 
possibility of duplicates among the source records, the data 
captured are likely to reflect accurately the testing practices 
across Asia in 2011.
The survey showed that 20% of laboratories surveyed in 
2011 were not accredited by international or national bodies 
and 47.5% did not participate in a Quality Assurance scheme, 
an aspect of testing practice that clearly requires immediate 
improvement.
The data collected in this survey indicate that, despite 
the high incidence of the EGFR mutation in Asian popula-
tions, EGFR mutation testing practices varied widely across 
the region in 2011. The survey revealed several areas where 
improvements are required, and may provoke changes in the 
health measures and/or policy in the individual countries by 
clarifying the differences on EGFR mutation testing among 
the countries. The data also provides a baseline against which 
the impact of the 2013 CAP/IASLC/AMP molecular testing 
guidelines,18 evolving histological classifications (e.g., the 
upcoming 2015 WHO classification), and development of 
multiplex mutation analyses can be assessed.
ACkNOwLEDGEMENTS
This investigator-initiated retrospective study was 
funded by AstraZeneca. The authors thank the staff who com-
pleted the online survey at the participating testing sites; 
the CRO, WorldWide Clinical Trials; and AstraZeneca’s 
Observational Research Centre.
Uploading and management of the online survey, and 
editorial assistance with drafting the manuscript were pro-
vided by Samantha Santangelo, PhD of MediTech Media Asia 
Pacific, funded by AstraZeneca.
REFERENCES
 1. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coin-
cidence in non small-cell lung cancer: Meta-analyses by ethnicity and 
histology (mutMap). Ann Oncol 2013;24:2371–2376.
 2. GLOBOCAN (IARC) 2012. Lung cancer fact sheet. http://globocan.iarc.
fr/Pages/fact_sheets_cancer.aspx. Accessed March 17, 2014.
 3. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key path-
ways in lung adenocarcinoma. Nature 2008;455:1069–1075.
 4. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. 
Lancet Oncol 2011;12:175–180.
 5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel 
in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
 6. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor recep-
tor gene and related genes as determinants of epidermal growth factor 
receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 
2007;98:1817–1824.
 7. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib 
(IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) 
as a first-line treatment for never smokers with advanced or metastatic 
adenocarcinoma of the lung. J Thorac Oncol 2009;4:S283–S284.
 8. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med 2010;362:2380–2388.
 9. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell 
lung cancer harbouring mutations of the epidermal growth factor receptor 
(WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 
2010;11:121–128.
 10. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group 
in collaboration with Groupe Français de Pneumo-Cancérologie and 
Associazione Italiana Oncologia Toracica. Erlotinib versus stan-
dard chemotherapy as first-line treatment for European patients 
445Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 3, March 2015 EGFR Mutation Testing Practices
with advanced EGFR mutation-positive non-small-cell lung can-
cer (EURTAC): A multicentre, open-label, randomised phase 3 trial. 
Lancet Oncol 2012;13:239–246.
 11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line 
treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, 
randomised, phase 3 study. Lancet Oncol 2011;12:735–742.
 12. Marchetti A, Normanno N, Pinto C, et al.; AIOM - SIAPEC-IAP; Italian 
Association of Medical Oncology; Italian Society of Anatomic Pathology 
and Diagnostic Cytopathology. Recommendations for mutational analy-
sis of EGFR in lung carcinoma. Pathologica 2010;102:119–126.
 13. Pirker R, Herth FJ, Kerr KM, et al.; European EGFR Workshop Group. 
Consensus for EGFR mutation testing in non-small cell lung cancer: 
Results from a European workshop. J Thorac Oncol 2010;5:1706–1713.
 14. Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment 
status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 
2012;77:371–375.
 15. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epider-
mal growth factor receptor mutations and clinicopathologic features in 
non-small cell lung cancers. Clin Cancer Res 2005;11:1167–1173.
 16. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction 
of gefitinib sensitivity by epidermal growth factor receptor gene mutation 
in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22–28.
 17. Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: 
A review of available methods and their use for analysis of tumour tissue 
and cytology samples. J Clin Pathol 2013;66:79–89.
 18. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guide-
line for selection of lung cancer patients for EGFR and ALK tyrosine 
kinase inhibitors: Guideline from the College of American Pathologists, 
International Association for the Study of Lung Cancer, and Association 
for Molecular Pathology. Arch Pathol Lab Med 2013;137:828–860.
 19. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation 
tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann 
Oncol 2012;23:2914–2919.
